Mednet Logo

For women with metastatic HER2 + breast cancer who achieve a complete response, how long do you continue on HER2-directed therapies?

Do you ever consider de-escalating or stopping therapy in this situation? What is your approach to this conversation?
3 Answers
Mednet Member
Mednet Member
Medical Oncology · Indiana University School of Medicine
Answered on

In nearly all cases, I would continue therapy until progression or unacceptable toxicity. Multiple studies have found an improvement in PFS and.or OS by continuing trastuzumab (or other HER2 inhibitor) after progression on trastuzumab.. Ask yourself this.....if continuing BEYOND progression is helpf...

Join for free or sign in to see the full answer

Mednet Member
Mednet MemberInvited Expert
Medical Oncology · UT Southwestern Medical Center
Answered on

I typically continue trastuzumab even after a complete response, although I might consider changing the backbone to avoid toxicity. For example, for someone with hormone receptor positive, HER2-positive disease who achieves a durable complete response on paclitaxel-trastuzumab, I might consider a tr...

Join for free or sign in to see the full answer

Mednet Member
Mednet Member
Medical Oncology · MOSC Medical College Kolenchery
Answered on

I think one unanswered question is how to manage women with HER2+ MBC who are exceptional responders with no active site of disease and are on single agent herceptin for 5+ years. Would you consider stopping the drug (drug holiday) and careful monitoring for disease progression? An MD Anderson regis...

Join for free or sign in to see the full answer